ClinicalTrials.gg
CompletedNCT01949545Updated May 2, 2017Results posted

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

A Phase 1 interventional study of Carfilzomib in Solid Tumors, Hematologic Malignancies and Hepatic Impairment, sponsored by Amgen. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Amgen · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
295th of 658
46 · median 40
Started
2013
with 30 others
Phase 1
195 of 821
35 open now
Registered
261st of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 295th largest by enrollment of the 658 interventional ones that give a count, is one of 31 that started in 2013, is one of 195 in phase 1, and was the 261st registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug.

03

Conditions studied

  • Solid Tumors
  • Hematologic Malignancies
  • Hepatic Impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or progressive advanced (solid tumors or hematologic malignancies)
  2. At least ≥ 2 prior treatment regimens for the underlying malignancy
  3. Confirmed advanced solid tumor or hematologic malignancy
  4. Measurable or evaluable disease
  5. Clinical diagnosis of chronic hepatic impairment that is stable with no acute worsening of liver failure within one month prior to enrollment. Hepatic impairment will be assessed as per National Cancer Institute Organ Dysfunction Working Group Criteria (NCI-ODWG) schema and will fall into one of the following three categories:

    • Cohort 2 (mild): > 1-1.5 × (ULN) or (AST) > ULN, but bilirubin ≤ ULN
    • Cohort 3 (moderate): ≥ 1.6-3 × ULN; any AST
    • Cohort 4 (severe): Bilirubin > 3 × ULN; any AST

    Exception to Inclusion Criterion #5 for Subjects with Normal Hepatic Function:

    All subjects enrolled with normal hepatic function (N=10) must meet all inclusion criteria as outlined with the exception of Inclusion Criterion

    #5, which should be substituted with the following criterion to be enrolled into the study:

    • Cohort 1 (normal hepatic function): Bilirubin ≤ ULN; AST ≤ ULN
  6. (ECOG) Performance Status 0-2
  7. (LVEF) ≥ 40%
  8. Adequate renal function (calculated ≥ 30 mL/min)
  9. Active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within the protocol-specified period prior to enrollment

Key Exclusion Criteria:

  1. Subjects with symptomatic or central nervous system (CNS) disease
  2. Significant neurotoxicity (Grade 2 with pain or higher) at the time of enrolment
  3. Known (HIV), virus (HBV) and virus (HCV) infection (Exception: Subjects with chronic or cleared HBV and HCV infection and stable liver function tests [bilirubin, AST] will be allowed)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Normal Hepatic Function

    Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.

    Drug: Carfilzomib

  • Experimental
    Mild Hepatic Impairment

    Participants with mild hepatic impairment (bilirubin \> 1-1.5 x ULN or AST \> ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.

    Drug: Carfilzomib

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment (bilirubin \> 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.

    Drug: Carfilzomib

  • Experimental
    Severe Hepatic Impairment

    (Bilirubin \> 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin \> 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.

    Drug: Carfilzomib

Interventions

  • Carfilzomib was administered by IV injection over 30 minutes

    Also known as: Kyprolis® (carfilzomib) for Injection

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m²

    The area under the curve from time zero (defined as the start of carfilzomib infusion) to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  2. Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²

    The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m²

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  2. Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m²

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  3. Clearance of Carfilzomib 27 mg/m²

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  4. Terminal Half-life of Carfilzomib 27 mg/m²

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  5. Mean Residence Time (MRT) of Carfilzomib 27 mg/m²

    Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  6. Volume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m²

    Time frame: Cycle 1 day 16 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  7. Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m²

    The area under the curve from time zero to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  8. Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m²

    The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  9. Maximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m²

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  10. Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m²

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  11. Terminal Half-life of Carfilzomib 56 mg/m²

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  12. Clearance of Carfilzomib 56 mg/m²

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  13. Mean Residence Time (MRT) of Carfilzomib 56 mg/m²

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  14. Volume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m²

    Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  15. Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-389/M14

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  16. Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-389/M14

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  17. Maximum Plasma Concentration (Cmax) for Metabolite PR-389/M14

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  18. Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-389/M14

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  19. Terminal Half-life for Metabolite PR-389/M14

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  20. Mean Residence Time (MRT) for Metabolite PR-389/M14

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  21. Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-413/M15

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  22. Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-413/M15

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  23. Maximum Plasma Concentration (Cmax) for Metabolite PR-413/M15

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  24. Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-413/M15

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  25. Terminal Half-life for Metabolite PR-413/M15

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  26. Mean Residence Time (MRT) for Metabolite PR-413/M15

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  27. Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-519/M16

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  28. Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-519/M16

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  29. Maximum Plasma Concentration (Cmax) for Metabolite PR-519/M16

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  30. Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-519/M16

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  31. Terminal Half-life for Metabolite PR-519/M16

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  32. Mean Residence Time (MRT) for Metabolite PR-519/M16

    Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.

  33. Number of Participants With Adverse Events (AEs)

    Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship. Adverse events were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, on a scale from 1 (mild) to 5 (death).

    Time frame: From the first dose of carfilzomib until 30 days after last dose; the overall median duration of treatment was 4.2 weeks

07

Results

Posted Oct 21, 2016

Participant flow

Participant flow — Overall Study
MilestoneNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Started1117144
Completed1117144
Not completed0000

Outcome measures

PrimaryArea Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m²

The area under the curve from time zero (defined as the start of carfilzomib infusion) to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m²
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m²378 ± 40.8546 ± 39.2477 ± 33.1—
Statistical analysis
  • Normal Hepatic Function vs Mild Hepatic Impairment · ANOVA · p = 0.02232 · Geometric mean ratio: 144.43 · 95% CI 111.48 to 187.12The geometric mean ratio was calculated by exponentiation of the differences in the least squares means, using log-transformed data, between the hepatic impairment cohort (test) and participants with normal hepatic function (reference).
  • Normal Hepatic Function vs Moderate Hepatic Impairment · ANOVA · p = 0.1812 · Geometric mean ratio: 126.08 · 95% CI 94.59 to 168.06The geometric mean ratio was calculated by exponentiation of the differences in the least squares means, using log-transformed data, between the hepatic impairment cohort (test) and participants with normal hepatic function (reference).
PrimaryArea Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²

The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²348 ± 35.4529 ± 40.3500 ± 38.4—
Statistical analysis
  • Normal Hepatic Function vs Mild Hepatic Impairment · ANOVA · p = 0.02137 · Geometric mean ratio: 151.84 · 95% CI 113.59 to 202.96The geometric mean ratio was calculated by exponentiation of the differences in the least squares means, using log-transformed data, between the hepatic impairment cohort (test) and participants with normal hepatic function (reference).
  • Normal Hepatic Function vs Moderate Hepatic Impairment · ANOVA · p = 0.07247 · Geometric mean ratio: 143.53 · 95% CI 103.28 to 199.45The geometric mean ratio was calculated by exponentiation of the differences in the least squares means, using log-transformed data, between the hepatic impairment cohort (test) and participants with normal hepatic function (reference).
SecondaryMaximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m²
Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m²
ng/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Maximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m²932 ± 58.41290 ± 47.51020 ± 43.7—
SecondaryTime to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m²
Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m²
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m²0.292 (0.250 to 0.500)0.458 (0.250 to 0.667)0.483 (0.233 to 0.750)—
SecondaryClearance of Carfilzomib 27 mg/m²
Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · L/hour
Clearance of Carfilzomib 27 mg/m²
L/hourNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Clearance of Carfilzomib 27 mg/m²157 ± 32.586.4 ± 50.9103 ± 43.9—
SecondaryTerminal Half-life of Carfilzomib 27 mg/m²
Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Terminal Half-life of Carfilzomib 27 mg/m²
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Terminal Half-life of Carfilzomib 27 mg/m²0.469 ± 22.80.541 ± 75.90.511 ± 219.4—
SecondaryMean Residence Time (MRT) of Carfilzomib 27 mg/m²
Time frame:
Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) of Carfilzomib 27 mg/m²
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Mean Residence Time (MRT) of Carfilzomib 27 mg/m²0.108 ± 60.60.167 ± 45.70.235 ± 70.4—
SecondaryVolume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m²
Time frame:
Cycle 1 day 16 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters
Volume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m²
litersNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Volume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m²16.9 ± 37.014.4 ± 58.124.2 ± 66.0—
SecondaryArea Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m²

The area under the curve from time zero to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m²
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m²765 ± 100.51107 ± 73.7927 ± 45.8—
SecondaryArea Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m²

The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.

Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m²
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m²609 ± 99.61108 ± 73.7929 ± 46.2—
SecondaryMaximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m²
Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m²
ng/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Maximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m²1697 ± 93.72733 ± 67.02119 ± 47.9—
SecondaryTime to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m²
Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m²
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m²0.300 (0.250 to 0.583)0.408 (0.250 to 0.683)0.400 (0.250 to 0.583)—
SecondaryTerminal Half-life of Carfilzomib 56 mg/m²
Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Terminal Half-life of Carfilzomib 56 mg/m²
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Terminal Half-life of Carfilzomib 56 mg/m²0.508 ± 54.70.621 ± 47.70.740 ± 137.7—
SecondaryClearance of Carfilzomib 56 mg/m²
Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · L/hour
Clearance of Carfilzomib 56 mg/m²
L/hourNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Clearance of Carfilzomib 56 mg/m²181 ± 95.992.0 ± 77.2121 ± 43.5—
SecondaryMean Residence Time (MRT) of Carfilzomib 56 mg/m²
Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) of Carfilzomib 56 mg/m²
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Mean Residence Time (MRT) of Carfilzomib 56 mg/m²0.0834 ± 195.60.161 ± 43.60.164 ± 30.7—
SecondaryVolume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m²
Time frame:
Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters
Volume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m²
litersNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Volume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m²15.0 ± 52.214.8 ± 51.919.8 ± 36.7—
SecondaryArea Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-389/M14
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-389/M14
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0463 ± 42.5417 ± 30.5385 ± 26.8—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0837 ± 26.8752 ± 29.7786 ± 20.3—
SecondaryArea Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-389/M14
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-389/M14
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 4, 11, 8, 0400 ± 19.3432 ± 29.9437 ± 32.7—
Cycle 2 Day 1 (56 mg/m²); N = 4, 6, 5, 0834 ± 6.3770 ± 27.2843 ± 22.3—
SecondaryMaximum Plasma Concentration (Cmax) for Metabolite PR-389/M14
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) for Metabolite PR-389/M14
ng/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0189 ± 32.5198 ± 22.7201 ± 26.5—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0381 ± 15.0345 ± 25.9513 ± 24.3—
SecondaryTime to Maximum Plasma Concentration (Tmax) for Metabolite PR-389/M14
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-389/M14
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 00.867 (0.583 to 1.52)0.792 (0.633 to 1.50)0.750 (0.583 to 1.00)—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 00.842 (0.750 to 1.48)0.992 (0.750 to 1.60)0.750 (0.650 to 0.783)—
SecondaryTerminal Half-life for Metabolite PR-389/M14
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Terminal Half-life for Metabolite PR-389/M14
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 4, 11, 8, 01.42 ± 10.31.20 ± 13.71.26 ± 18.0—
Cycle 2 Day 1 (56 mg/m²); N = 4, 6, 5, 01.32 ± 15.31.30 ± 16.11.07 ± 13.6—
SecondaryMean Residence Time (MRT) for Metabolite PR-389/M14
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) for Metabolite PR-389/M14
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 4, 11, 8, 02.42 ± 11.42.13 ± 12.22.14 ± 16.0—
Cycle 2 Day 1 (56 mg/m²); N = 4, 6, 5, 02.25 ± 10.82.27 ± 15.81.78 ± 11.2—
SecondaryArea Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-413/M15
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-413/M15
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 050.1 ± 39.556.7 ± 33.985.5 ± 36.6—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0106 ± 33.7119 ± 38.9173 ± 17.8—
SecondaryArea Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-413/M15
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-413/M15
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 13, 8, 056.6 ± 43.760.8 ± 32.692.9 ± 41.7—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0116 ± 36.9132 ± 41.0186 ± 18.2—
SecondaryMaximum Plasma Concentration (Cmax) for Metabolite PR-413/M15
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) for Metabolite PR-413/M15
ng/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 027.8 ± 30.533.9 ± 30.746.3 ± 26.6—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 059.4 ± 27.566.0 ± 37.2103 ± 19.5—
SecondaryTime to Maximum Plasma Concentration (Tmax) for Metabolite PR-413/M15
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-413/M15
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 00.750 (0.583 to 0.767)0.767 (0.583 to 1.00)0.650 (0.583 to 1.10)—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 00.717 (0.600 to 1.00)0.800 (0.467 to 1.08)0.750 (0.617 to 0.750)—
SecondaryTerminal Half-life for Metabolite PR-413/M15
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Terminal Half-life for Metabolite PR-413/M15
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 13, 8, 01.34 ± 18.91.25 ± 13.61.23 ± 17.6—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 01.18 ± 21.81.24 ± 10.21.07 ± 16.0—
SecondaryMean Residence Time (MRT) for Metabolite PR-413/M15
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) for Metabolite PR-413/M15
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 13, 8, 02.13 ± 15.82.02 ± 8.82.04 ± 14.6—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 01.96 ± 18.92.09 ± 8.01.83 ± 8.9—
SecondaryArea Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-519/M16
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-519/M16
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0125 ± 27.6136 ± 45.2228 ± 37.3—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0278 ± 23.4311 ± 42.9463 ± 24.5—
SecondaryArea Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-519/M16
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-519/M16
ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 8, 0127 ± 27.8138 ± 44.9235 ± 39.4—
Cycle 2 Day 1 (56 mg/m²); N = 7, 8, 5, 0281 ± 25.6314 ± 42.7465 ± 24.4—
SecondaryMaximum Plasma Concentration (Cmax) for Metabolite PR-519/M16
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) for Metabolite PR-519/M16
ng/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0145 ± 30.7160 ± 42.0257 ± 43.6—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0314 ± 33.6349 ± 39.5546 ± 23.4—
SecondaryTime to Maximum Plasma Concentration (Tmax) for Metabolite PR-519/M16
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-519/M16
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 00.500 (0.250 to 0.667)0.600 (0.250 to 0.750)0.700 (0.583 to 0.850)—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 00.483 (0.250 to 0.617)0.592 (0.250 to 0.850)0.583 (0.467 to 0.650)—
SecondaryTerminal Half-life for Metabolite PR-519/M16
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Terminal Half-life for Metabolite PR-519/M16
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 8, 00.786 ± 14.00.728 ± 22.60.673 ± 13.6—
Cycle 2 Day 1 (56 mg/m²); N = 7, 8, 5, 00.748 ± 22.20.680 ± 10.70.601 ± 8.2—
SecondaryMean Residence Time (MRT) for Metabolite PR-519/M16
Time frame:
Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) for Metabolite PR-519/M16
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 8, 01.01 ± 11.30.961 ± 29.10.994 ± 13.3—
Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 00.994 ± 9.01.00 ± 14.20.909 ± 7.8—
SecondaryNumber of Participants With Adverse Events (AEs)

Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship. Adverse events were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, on a scale from 1 (mild) to 5 (death).

Time frame:
From the first dose of carfilzomib until 30 days after last dose; the overall median duration of treatment was 4.2 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Any adverse event1017144
Adverse event Grade ≥ 3712133
Serious adverse events31084
Leading to discontinuation of carfilzomib1240
Fatal adverse events1413
Treatment-related adverse events (TRAE)813121
Treatment-related adverse events Grade ≥ 32580
Treatment-related serious adverse events0340
TRAE leading to discontinuation of carfilzomib1030
Treatment-related fatal adverse events0200

Adverse events

Collected over From the first dose of carfilzomib until 30 days after last dose; the overall median duration of treatment was 4.2 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Hepatic Function—3/11 (27.3%)10/11 (90.9%)
Mild Hepatic Impairment—10/17 (58.8%)17/17 (100%)
Moderate Hepatic Impairment—8/14 (57.1%)14/14 (100%)
Severe Hepatic Impairment—4/4 (100%)3/4 (75%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Hepatic encephalopathyNervous system disorders0/110/170/142/4
Acute kidney injuryRenal and urinary disorders0/110/171/142/4
Multi-organ failureGeneral disorders0/110/170/141/4
Acute hepatic failureHepatobiliary disorders0/110/170/141/4
Bacterial sepsisInfections and infestations0/110/170/141/4
Septic shockInfections and infestations0/110/170/141/4
AscitesGastrointestinal disorders0/110/173/140/4
Blood bilirubin increasedInvestigations0/110/172/140/4
Lower respiratory tract infectionInfections and infestations1/111/170/140/4
PneumoniaInfections and infestations1/111/170/140/4
Most frequent other events
Showing 10 of 142
Most frequent other events
EventNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
FatigueGeneral disorders8/117/178/140/4
Blood bilirubin increasedInvestigations0/111/179/140/4
AnaemiaBlood and lymphatic system disorders6/1110/173/142/4
DiarrhoeaGastrointestinal disorders4/114/174/141/4
Oedema peripheralGeneral disorders4/112/175/140/4
NauseaGastrointestinal disorders3/115/175/140/4
ConstipationGastrointestinal disorders1/115/174/140/4
Alanine aminotransferase increasedInvestigations1/115/174/140/4
Decreased appetiteMetabolism and nutrition disorders3/115/172/140/4
ThrombocytopeniaBlood and lymphatic system disorders0/111/174/140/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Mean68.5 ± 8.259.5 ± 9.161.0 ± 7.956.3 ± 10.961.8 ± 9.3
Age, Customized
Age, Customized(participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
< 65 years3128326
≥ 65 years856120
Sex: Female, Male
Sex: Female, Male(Participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Female285318
Male999128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Black01102
White111313441
Not reported03003
08

Study locations

11 sites
  • Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Duke Cancer Institute
    Durham, North Carolina, United States
  • Gabrail Cancer Center
    Canton, Ohio, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee, United States
  • Evergreen Hematology and Oncology
    Spokane, Washington, United States
  • Institut Gustave Roussy
    Paris, Villejuif Cedex, France
  • University Medical Centre Utrecht
    Utrecht, Netherlands
  • Northern Ireland Cancer Trials Centre - Queen's University Belfast TriaIs Centre
    Belfast, Northern Ireland, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Scotland, United Kingdom
  • Velindre Hospital
    Cardlff, Wales, United Kingdom
  • Sir Bobby Robson Cancer Trials Research Centre
    Newcastle, United Kingdom
09

References and documents

Publications

  • Brown J, Plummer R, Bauer TM, Anthony S, Sarantopoulos J, De Vos F, White M, Schupp M, Ou Y, Vaishampayan U. Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Exp Hematol Oncol. 2017 Oct 3;6:27. doi: 10.1186/s40164-017-0086-1. eCollection 2017. PubMed 29026685 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2013
First posted
Sep 24, 2013
Start
Oct 2013
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Results first posted
Oct 21, 2016
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01949545
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 24, 2013
Start date
Oct 2013
Primary completion
Aug 2015
Completion
Sep 2015
Results posted
Oct 21, 2016
Last update
May 2, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion